Company
Headquarters: Uppsala, Sweden
Employees: 36
kr291.6 Million
SEK as of Jan. 1, 2024
US$29.0 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Bio-Works Technologies AB (publ), a biotechnology company, researches, develops, manufactures, and supplies agarose-based separation products to purify proteins, peptides, and other biomolecules primarily in Sweden. It offers activated and affinity resins; BabyBio columns; immobilized metal-ion affinity chromatography resins; ion exchange resins; OptioBio glass columns; screening kits; and size exclusion chromatography resins. The company's products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications. Bio-Works Technologies AB (publ) founded in 2006 and is headquartered in Uppsala, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Bio-Works Technologies AB has the following listings and related stock indices.
Stock: OMX: BIOWKS wb_incandescent